Drugs / Methamphetamine

Methamphetamine

Drug Prescription products are available in the U.S.; the drug is a Schedule II controlled substance.

CNS stimulant (serotonin-norepinephrine-dopamine releasing agent)

Registered trials
13
Ongoing
3/ 23%
Completed
9
Indications
2

Approved indications

Indication
ADHD
Weight loss (obesity/overweight)

Clinical trial landscape

13 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.

Phase Total Ongoing Completed Split
Phase 1 5 0 4
Early Phase 1 5 1 4
Phase 2 2 2 0
Not applicable 1 0 1
All phases 13 3 9

Ongoing Completed Balance withdrawn, terminated, or status unreported.

Study records: ClinicalTrials.gov →

Mechanism of action

Acts as a serotonin-norepinephrine-dopamine releasing agent and CNS stimulant.

Recent developments